Leanne Ward
Co-Applicant
Professor of Pediatrics and Tier 1 Clinical Research Chair in Pediatric Bone Disorders at uOttawa | Medical Director of the CHEO Genetic and Metabolic Bone Disease Clinic
Scientific Director of the Ottawa Pediatric Bone Health Research Group | Pediatric Endocrinologist at CHEO
NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research
Email LeanneResearch Interests: children, osteoporosis, osteogenesis imperfecta, bisphosphonate therapy, skeletal dysplasias, bone health, fractures, bone density, glucocorticoid-induced osteoporosis, x-linked hypophosphatemia, achondroplasia, duchenne muscular dystrophy and hypophospha
Academic web profileGoogle Scholar profile
Biography
Dr. Leanne Ward is a Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa where she holds a Tier 1 Research Chair in Pediatric Bone Disorders. Dr. Ward is also cross-appointed to the Department of Surgery given strong clinical and research ties to the Division of Orthopedics. She is the Scientific Director of The Ottawa Pediatric Bone Health Research Group, The Medical Director of the Pediatric Osteology Clinic at the Children’s Hospital of Eastern Ontario (CHEO), and a pediatric endocrinologist-osteologist in the CHEO Division of Endocrinology. In 2014, she founded The Canadian Consortium for Children’s Bone Health, a national, multi-disciplinary network of clinicians and scientists that fosters health professional education and research in childhood-onset bone disorders (bonescanada.org). She is also a Steering Committee Member of the International Society of Children’s Bone Health (ISCBH) and the Founder and Director of the Canadian Alliance for Rare Disorders o the Skeleton.
Dr. Ward’s research program is dedicated to the diagnosis and treatment of childhood-onset bone disorders including skeletal dysplasias (i.e. osteogenesis imperfecta and achondroplasia), genetic forms of rickets, hypophosphatasia and osteoporosis due to chronic illnesses (i.e. childhood cancer and Duchenne muscular dystrophy). The Ward lab has a particular focus on therapeutic trials in childhood-onset bone disorders, emphasizing skeletal health outcomes quantified through central skeletal imaging, and the study of novel drugs to mitigate the functional consequences of rare bone diseases. The Ward lab’s signature is local-to-global collaborative engagement with clinicians, researchers and the patient community in key areas that span orthopedics, genetics, radiology, endocrinology, dentistry, audiology, allied health, biomedical statistics and clinical trial operations.
Dr. Ward has held sustained funding from the Canadian Institutes of Health Research since 2003, published over 300 book chapters, abstracts and manuscripts, and delivered over 130 international invited speaking engagements. She works closely with patient advocacy groups to promote patient education and access to rare disease care, including the Canadian Organization for Rare Disorders, The Canadian Osteogenesis Imperfecta Society, The Canadian XLH Network, Parent Project Muscular Dystrophy, Defeat Duchenne Canada and Soft Bones Canada. In 2019, Dr. Ward was named a Fellow of the American Society of Bone and Mineral Research, an award in recognition of significant lifetime contributions to bone and mineral science.
Recent Publications
Grimbly, C, Ward, LM, Ryabets-Lienhard, A, Chen, I, Molakalapalli, S, Lin, L et al.. Children with X-linked hypophosphatemia have hypertension and left ventricular hypertrophy associated with obesity. J Bone Miner Res. 2026. PMID:42831698
Li, O, Ward, LM, Griffith, LE, Anderson, LN, Wong, AKO, Adachi, JD et al.. The Muscle-Bone Unit in Children and Adolescents: Insights from the Canadian Health Measures Survey. J Bone Miner Res. 2026. PMID:42789064
Sbrocchi, AM, Ahmet, A, Kinnett, K, Lautatzis, ME, McMillan, HJ, Apkon, S et al.. A structured approach to address variability in the global management of adrenal insufficiency in Duchenne muscular dystrophy: the 2025 PJ Nicholoff steroid protocol. Front Neurol. 2026.17 1926817 PMID:42787106
Ing, SW, Bowden, SA, Dahir, KM, Florenzano, P, Holm, IA, Khan, S et al.. Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults with X-Linked Hypophosphatemia (XLH): A 3-Year Follow-Up of the XLH Disease Monitoring Program. J Bone Miner Res. 2026. PMID:42777116
Weber, DR, Ahmet, A, Kinnett, K, Lautatzis, ME, McMillan, HJ, Apkon, S et al.. Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions. J Neuromuscul Dis. 2026. 22143602261485046 PMID:42770351
Kim, H, Ward, LM, Thabane, L, Papaioannou, A, Wong, AKO, Adachi, JD et al.. The associations of obesity and other covariates with bone turnover markers in children and adolescents. Bone. 2026.213 118092 PMID:42749104
Halloun, R, Jackowski, S, Scharke, M, Dang, UJ, Alshammri, F, Ma, J et al.. Total body and appendicular lean mass by dual-energy X-ray absorptiometry are highly associated with muscle function and bone mineral density in Becker muscular dystrophy. J Neuromuscul Dis. 2026. 22143602261476364 PMID:42663311
Minisola, S, Jan de Beur, SM, Carpenter, TO, Dahir, KM, Zanchetta, MB, Ward, L et al.. Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review. Calcif Tissue Int. 2026.117 (1) PMID:42573821
Tobin, RA, Dang, UJ, Hagerty, L, Ward, LM, Rooman, R, Konopka, KH et al.. Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy. Sci Rep. 2026.16 (1) PMID:42547787
Clemens, PR, Berglund, A, Schiava, M, James, MK, McDermott, MP, Bushby, K et al.. Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial. Neurology. 2026.107 (5)e218498 PMID:42531535
See more on PubMed